-The Hindu Instead of opening a debate on the Gadgil panel's report on the Western Ghats, the government has chosen to sideline and replace it with another by an alternate group This is a challenging time in India's development history where a number of tenets of environmental governance are being questioned by the imperative of growth. Environmental governance in India is under assault, and is thus in need of both fresh thinking,...

-PTI The Supreme Court today agreed to constitute a committee headed by an eminent jurist to finalise the draft rules for dealing with sexual harassment complaints of women, including lady lawyers, working at the apex court. A bench, headed by Chief Justice Altamas Kabir, said the name of the chairman of the Committee, which will also go into various other issues raised in the report prepared on its order, would be decided...

KEY TRENDS   • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8   • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...

-The Hindustan Times Cancer drugs will cost almost 25% less if the regulator implements a new formula that calls for a price cap. The price regulator National Pharmaceutical Pricing Authority (NPPA) is considering a pricing mechanism similar to the one for insulin products - which has brought down prices by up to 40% - for 33 cancer drugs, most of them generics. Basically, the lowest price from the list of drugs in a...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...